Assessing the current dealmaking environment for psychedelic medicine.

from Scrip Podcasts · host Norstella

Joseph Haas and Emma Wille overview the dealmaking environment for psychedelic medicine given recent developments in the space: Eli Lilly's $2.8 billion acquisition of AtaiBeckley in July, the imminent FDA filing of Compass Pathways' COMP360 for treatment-resistant depression and a more relaxed regulatory environment for psychedelic therapies under the current administration.

Episode metadata supplied by the publisher feed · Published Sep 18, 2026

Embed this episode

Attribution link and audio player

Ready to play

Assessing the current dealmaking environment for psychedelic medicine.

0:00 19:41

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Scrip Podcasts?

This episode is 19 minutes long.

When was this Scrip Podcasts episode published?

This episode was published on September 18, 2026.

Can I download this Scrip Podcasts episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!